Buy & Sell McCormick & Company, Incorporated (MKC) – McCormick & Company, Incorporated Price Today
Aura AI Summary
Key Stats
- $12.85BMarket Cap
- Consumer StaplesSector
- -35.81%3M Drawdown
- $17.60BEnterprise Value
- 4.02%Dividend Yield
- 73 daysTypical Hold Time
McCormick & Company, Incorporated (MKC) is currently valued at a market capitalization of $12.85B, with an enterprise value of $17.60B. Over the past 52 weeks, McCormick & Company, Incorporated has traded between a low of $45.6 and a high of $77.57, highlighting its annual price range. Over the past three months, McCormick & Company, Incorporated has recorded a drawdown of -35.81%, reflecting recent price volatility. McCormick & Company, Incorporated offers a dividend yield of 4.02%, with the most recent dividend of $0.48 paid on 20 Apr 26. On average, investors hold McCormick & Company, Incorporated for approximately 73 days, indicating typical investor behavior on the platform.
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Most Recent News
Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...

Investigation launched into Prestige Consumer Healthcare over missed earnings and undisclosed acquisition
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...

Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...
